ID: ALA24398

Max Phase: Preclinical

Molecular Formula: C24H29N3O5

Molecular Weight: 439.51

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NO)[C@@H](NCC1CC1)[C@@H](Cc1cccc(O)c1)C(=O)N[C@H]1c2ccccc2C[C@H]1O

Standard InChI:  InChI=1S/C24H29N3O5/c28-17-6-3-4-15(10-17)11-19(22(24(31)27-32)25-13-14-8-9-14)23(30)26-21-18-7-2-1-5-16(18)12-20(21)29/h1-7,10,14,19-22,25,28-29,32H,8-9,11-13H2,(H,26,30)(H,27,31)/t19-,20-,21+,22+/m1/s1

Standard InChI Key:  UACUZULRKJKTHE-CZYKHXBRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 439.51

Molecular Weight (Monoisotopic): 439.2107

AlogP: 1.20

#Rotatable Bonds: 9

Polar Surface Area: 130.92

Molecular Species: NEUTRAL

HBA: 6

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.65

CX Basic pKa: 7.80

CX LogP: 1.21

CX LogD: 0.92

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.26

Np Likeness Score: 0.43

References

1. Cherney RJ, Mo R, Meyer DT, Wang L, Yao W, Wasserman ZR, Liu RQ, Covington MB, Tortorella MD, Arner EC, Qian M, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Decicco CP..  (2003)  Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.,  13  (7): [PMID:12657268] [10.1016/s0960-894x(03)00124-0]

2. Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP..  (2001)  Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.,  44  (21): [PMID:11585439] [10.1021/jm015533c]

3. Georgiadis D, Yiotakis A..  (2008)  Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.,  16  (19): [PMID:18790648] [10.1016/j.bmc.2008.08.058]

4. Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T..  (2011)  Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.,  54  (8): [PMID:21417219] [10.1021/jm101609j]

5. Nuti E, Santamaria S, Casalini F, Yamamoto K, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Marini AM, Salerno S, Taliani S, Da Settimo F, Nagase H, Rossello A..  (2013)  Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.,  62  [PMID:23376997] [10.1016/j.ejmech.2012.12.058]

6. Cuffaro D, Ciccone L, Rossello A, Nuti E, Santamaria S..  (2022)  Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition.,  65  (20.0): [PMID:36250680] [10.1021/acs.jmedchem.2c01177]

Source

Source(1):

• Scientific Literature